Showing 8581-8590 of 20878 results for "".
Is It Familial or Multifactorial Chylomicronemia Syndrome?
https://reachmd.com/programs/on-the-frontlines-of-familial-chylomicronemia-syndrome/familial-vs-multifactorial-chylomicronemia/56942/Although familial chylomicronemia syndrome (FCS) and multifactorial chylomicronemia syndrome (MCS) can both cause severely elevated triglyceride levels, important differences in their underlying biology can affect diagnosis, treatment, and patient outcomes. Joining Dr. Steve Jackson to discuss the iExploring the Future of Psoriasis Treatment with Oral Agents
https://reachmd.com/programs/dermconsult/future-psoriasis-treatment-oral-agents/39685/Novel oral therapies are expanding the possibilities for personalized care in psoriasis, offering biologic-like efficacy with greater flexibility. Join Dr. Christopher Bunick as he discusses the evolving role of oral agents in the future of psoriasis treatment and the importance of real-world data iLowering Lipids Through Therapeutic Lifestyle Change
https://reachmd.com/programs/lipid-luminations/lowering-lipids-through-therapeutic-lifestyle-change/3943/Cindy Conroy, a registered dietitian at the Iowa Heart Center Lipid Clinic, discusses with host Dr. Larry Kaskel practical approaches to helping patients implement a successful lifestyle change program. Ms. Conroy emphasizes the importance of educating patients about the relationship between sugar iAddressing Vascular Plaque Ruptures
https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/addressing-vascular-plaque-ruptures/3131/A ruptured vascular plaque with subsequent thrombus often triggers the heart attack that occurs without warning. How do we identify and treat at-risk cardiac patients? Host Dr. Lee Freedman discusses an array of tools to evaluate plaque burden and promote plaque stabilization with Dr. Emile Mohler IGoing Home and Staying Home: Reducing Readmissions
https://reachmd.com/programs/heart-matters/going-home-and-staying-home-reducing-readmissions/4576/The transition from inpatient to outpatient status is a vulnerable spot in our health care system: more than one in four patients with congestive heart failure are back in the hospital within 30 days of discharge, and readmission rates for a host of other conditions are above 20 percent. The right iOverbooking: A Boost to Practice Productivity?
https://reachmd.com/programs/clinicians-roundtable/overbooking-a-boost-to-practice-productivity/2661/Overbooking: the airlines do it. Should medical professionals do it too? Host Dr. Michael Greenberg weighs the evidence with Linda LaGanga, PhD, an instructor at the University of Colorado Leeds School of Business, and co-author of the publication, "Clinic Overbooking to Improve Patient Access and IEmergencies at 30,000 Feet: Good Samaritan Laws
https://reachmd.com/programs/clinicians-roundtable/emergencies-at-30000-feet-good-samaritan-laws/980/You're a healthcare professional and you've just answered the call to help a sick airline passenger while cruising at 30,000 feet. No resources; no support staff; no emergency landing for another 1/2 hour. No problem! Tune to hear how you're covered under "federal" Good Samaritan Laws for medical iAducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
https://reachmd.com/programs/neurofrontiers/aducanumab-in-early-alzheimers-slowing-cognitive-and-functional-decline/40002/Aducanumab has historically been a topic of debate in Alzheimer’s treatment, but new data from the EMERGE trial offers further clarity on this anti-amyloid antibody. A detailed analysis of item-level data reveals that high-dose aducanumab slowed disease progression across multiple clinical domains—iIs There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
https://reachmd.com/programs/project-oncology/is-there-a-role-for-primary-tumor-surgery-in-metastatic-breast-cancer/67358/Trial data on primary tumor surgery in de novo metastatic breast cancer remain conflicting. In this episode of Project Oncology, Dr. Lajos Pusztai unpacks these contradictory results across major trials and explains why a hidden variable in how the rest of the disease is treated may be driving the iEarly Recognition of ATTR-CM: Key Signs and Diagnostic Strategies
https://reachmd.com/programs/heart-matters/early-recognition-attr-cm-signs-diagnosis/49067/With increasing recognition and more accessible diagnostic tools, ATTR-CM can no longer be overlooked in patients with atypical heart failure presentations. Dr. Valmiki Maharaj shades insights on connecting clinical clues, confirming diagnosis efficiently, and acting earlier to meaningfully i